Share Name Share Symbol Market Type Share ISIN Share Description
Omega Dia LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -1.09% 22.625p 22.00p 23.25p 23.125p 22.625p 22.875p 29,900 10:04:40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 14.2 0.7 1.1 20.6 28.72

Omega Diagnostics (ODX) Latest News

More Omega Diagnostics News
Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Share Charts

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date Time Title Posts
21/9/201714:11Omega Diagnostics - nicely poised for significant growth246
01/8/201708:17Omega Diagnostics1,774

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

Omega Diagnostics Daily Update: Omega Dia is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ODX. The last closing price for Omega Diagnostics was 22.88p.
Omega Dia has a 4 week average price of 21.38p and a 12 week average price of 17.75p.
The 1 year high share price is 28.25p while the 1 year low share price is currently 15.75p.
There are currently 126,959,060 shares in issue and the average daily traded volume is 27,912 shares. The market capitalisation of Omega Dia is £28,724,487.33.
rivaldo: Good to see the share price on a small uptrend post-fundraising. Finncap's latest forecasts are for 1.1p EPS this year, rising to 2.1p EPS next year as some of the blue sky opportunities begin to commercialise. They currently have a 30p target. At that rate of growth it's possible to see a 40p-50p share price in 9 months to a year's time assuming successful achievement of those forecasts - or an outlook which confirms as such.
barrywhit: Hyperboreus, It is disappointing, the company would have expected a higher take up but perhaps the shareholders were disappointed with the share price drop to get the placing away, but you also need available funds, I was only prepared to sell one of my holdings to free up funds in my SIPP....Lets see if they release any news in the next few weeks....
rivaldo: Excellent news all round, particularly the good start to the new year. However, the fundraising process will have started a few weeks or so ago - probably around the start of June judging by the share price chart! I note that Sneller and LGIM are picking up £730,000 of the placing shares and the directors another £300,000 between them - pretty impressive commitments.
barrywhit: good to see the Directors are taking shares at 18p after letting the share price drift down from a high of 27.5p bid.....
hyperboreus: I suppose this post has no direct relevance with ODX but it will be interesting to observe what happens tomorrow with AVG/HAYT as Richard Edgar Sneller who we are all very familiar with on this board still owns 3,680,000 shares (6.64%) in HAYT. If AVG go with a cash offer for HAYT he could probably take ODX out if the share price keeps falling! 😂
hyperboreus: Only a couple of months ago from the trading statement: "Outlook We have reached a significant milestone in achieving design freeze with our VISITECT® CD4 development programme. We remain confident in completing the verification and validation programme to deliver a unique product which we believe will meet a large unmet medical need for people living with HIV infections in resource-limited countries. We have also been successful in achieving full operational capability with our manufacturing facility in Pune, India. Whilst we have already indicated we expect to achieve modest sales with our Malaria range of tests this year, we believe we have created a valuable asset which can grow shareholder value in the years ahead. We are encouraged by the ongoing performance of our core business. Our Food Intolerance division continues to grow at a healthy rate and we are reviewing initiatives as to how we may grow this business in North America. Our allergy business in Germany achieved a 3% increase in euro denominated turnover, reversing a declining trend in recent years. The development updates we have outlined and the investments we have made in people and infrastructure give us much confidence for the future." I too have increased my holding significantly of late and have taken the opportunity to increase it further this afternoon given the severe pullback in the share price. Someone has been offloading for quite a few weeks now but I am confident that the tide will turn shortly 👍 Just for the record I am still showing a paper profit at this level but not by much now!
barrywhit: Its just what happens to ODX, just look at the chart for the last 4 years, there is never any news from the company to support a rise in share price, still awaiting the IDS update, Results sometime in mid July, no news on field trials, no news on the India manufacturing since the last trading update, too few news releases, no new investors only us long term will hopefully come good in the end, at least I hope so as I have doubled my holding in the last couple of months.....
buywell3: To what extent is or has CD4 been the catalyst for the last rise ? That needs answering, I have already posted my thoughts . I think the BOD was extremely premature in informing the market of this product when it was clearly beset by some issues which have dragged on. The share price to date has been held up by a single buyer it seems Which in itself has some risk I also raised the issue re licence .... which I see as another unresolved risk Then there is India which I have not even bothered to look into till the chart resolves itself The share might now rise due to the 'buywell effect'' it happens quite often
hyperboreus: Looking like you might get your wish longshanks re 16.5p Been having a really in depth look at all the director share options and the first tranche issued to Evans, Shepherd and Harbinson with exercise price at 19p expire on 10 December 2018 having been issued on 10 December 2008. I am sure they would have been expecting ODX's share price to be much higher by now over 9 years later as it has gone nowhere really since then. The next sizeable batch issued to Shepherd, Harbinson and Grewal with exercise price at 14.5p expire on 5 July 2022 but share price must be 25p or higher. Interestingly David Evans doesn't have any other options other than the one which expires next December, but having said that he was very generously 'allowed' to purchase 2,760,134 shares at 12p on 17 Dec 2010 in a private placing in relation to the purchase of the ALLERGOPHARMA IVD BUSINESS. His average share price purchase by the way is 12.81p, Jag Grewal's is 19.92p, not so easy to work out Harbinson's and Shepherd's as they they were directors in ODX before reverse takeover in 2006 but my best guess for Harbinson is 12.88p and 9.38p for Shepherd. My average share price in ODX has gone up significantly from my first purchase in April 2012 at 10.25p but at just over 16p I am still confident that exciting times are ahead, just not sure how long I might have to wait like the rest of us!
gary38: Omega Diagnostics Group PLC Holding(s) in CompanyIntraday Omega Diagnostics ChartIntraday Omega Diagnostics Chart09/06/2016 8:07amUK Regulatory (RNS & others)TIDMODXRNS Number : 7240AOmega Diagnostics Group PLC09 June 2016TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) --------------------------------------------------------------------------------------------- 1. Identity of the issuer or Omega Diagnostics Group the underlying issuer plc of existing shares to which voting rights are attached: (ii) --------------------------------------------------------------- ---------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): --------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights X ------------------------------------------------------------------- ------------------------ An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------- ------------------------ An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------- ------------------------ An event changing the breakdown of voting rights ------------------------------------------------------------------- ------------------------ Other (please specify): --------------------------------------------------------- -------- ------------------------ 3. Full name of person(s) Richard Edgar Sneller subject to the notification obligation: (iii) ----------------------------------------------------------- -------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ----------------------------------------------------------- -------------------------------- 5. Date of the transaction 8(th) June 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- -------------------------------- 6. Date on which issuer 8(th) June 2016 notified: ----------------------------------------------------------- -------------------------------- 7. Threshold(s) that is/are >6% crossed or reached: (vi, vii) ----------------------------------------------------------- -------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix)---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ------------- --------------- --------------- -------------- -------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- -------------- ------------ ------------ ------------ ----------- GB00B1VCP282 6,515,000 6,515,000 6,765,000 6,765,000 6.22% ------------- --------------- --------------- -------------- ------------ ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------- ---------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) --------------- ------------- ------------- ---------------- ---------------------------- ----------------------- Nominal Delta --------------- ------------- ------------- ---------------- ---------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 6,765,000 6.22% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ------------------------------------------------------------------------------- Proxy Voting: ------------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------------- ---------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- ---------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- ---------------- 13. Additional information: ------------------------------------------------------------- ---------------- 14. Contact name: Richard Sneller ------------------------------------------------------------- ---------------- 15. Contact telephone number: 0131 275 2198 ------------------------------------------------------------- ---------------- This information is provided by RNSThe company news service from the London Stock ExchangeENDHOLUKRWRNSANRRR(END) Dow Jones NewswiresJune 09, 2016 04:07 ET (08:07 GMT)Omega Diagnostics Share Price TodayOmega Diagnostics Share Price ChartOmega Diagnostics Share ChatOmega Diagnostics NewsOmega Diagnostics Share Price HistoryOmega Diagnostics DividendOmega Diagnostics TradesOmega Diagnostics Level 2Add Omega Diagnostics to WatchlistAdd Omega Diagnostics to your PortfolioOmega Diagnostics Share Price AlertSwitch to Desktop View By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & ConditionsShare and Investment Glossary Investment Warning Copyright © 1999 - 2016 Cookie and Privacy Policy
Omega Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170923 10:51:53